Sunho Biologics says auditor switch aims to break 2025 audit impasse, meet resumption deadlines

PUBT · 1d ago
Sunho Biologics says auditor switch aims to break 2025 audit impasse, meet resumption deadlines
  • Sunho Biologics issued a supplemental clarification on its auditor change, outlining delays in the 2025 annual audit tied to service-agreement verification.
  • Zhonghui Anda sought more time in March, warned it could resign, then resigned with immediate effect on June 5.
  • Outstanding audit work centered on scope limits in confirming counterparties and commercial substance; key third-party information remained unavailable.
  • KTC was appointed to fill the vacancy; it budgeted about 3 million audit hours and plans to use a PRC partner firm to accelerate testing.
  • Shares have been suspended since April 1 pending publication of the 2025 annual results; KTC is targeting a draft report by late September.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262892), on July 30, 2026, and is solely responsible for the information contained therein.